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Abstract 
Background: Primaquine is an important gametocytocidal drug that is combined with conventional malaria treat-
ment for prevention of Plasmodium falciparum malaria transmission. Primaquine has been administered together on 
the first or the last day of conventional treatment but the impact of primaquine timing has never been examined. This 
study aimed to assess safety, efficacy and optimal timing of single full-dose (0.75 mg/kg) primaquine when added to 
a standard 6-dose regimen of artemether–lumefantrine (AL).
Methods: In an individual-level randomized controlled trial, enrolled participants who were G6PD normal and had 
uncomplicated P. falciparum malaria were randomly assigned to receive: AL only; AL and a single 0.75 mg/kg pri-
maquine dose on the first day of AL (day 1); or AL and single 0.75 mg//kg primaquine on the last day of AL (day 3). 
On days 2, 3, 4, 8, 11 and 15, gametocytes were assessed and quantified by microscope and quantitative nuclear acid 
sequence based quantification (QT-NASBA).
Results: Overall, 111 participants aged between 3 and 17 years were randomly allocated to receive AL only (36) or 
combined with primaquine on day 1 (38), or primaquine on day 3 (37). Day 4 gametocyte prevalence in AL + day 
1 primaquine was half the level seen in either AL + day 3 primaquine or AL only arm (11% [4/35] vs 26% [8/31] and 
27% [8/30], respectively) albeit not statistically significant. A similar trend of lower gametocyte in the AL + day 1 pri-
maquine verses AL + day 3 primaquine or AL only arm was observed in mean gametocyte density. Mean (sd) haemo-
globin level in AL + day 3 primaquine arm recovered from -0.42(1.2) g/dl on day 2 to 0.35 (1.5) g/dl on day 15 of follow 
up. This was not the case in AL only and AL + day 1 primaquine arms during the same follow-up period, although the 
difference was not statistically significant (p = 318). No serious adverse events reported in the study. Across arms, 23% 
(26/111) of participants reported a total of 31 mild adverse events and the difference was not statistically significant 
(p = 0.477).
Conclusion: Primaquine administration on the first day of AL is well tolerated and as safe as later administration. 
Whilst the World Health Organization currently recommends a lower dose of primaquine (0.25 mg/kg), the findings 
are supportive of early primaquine administration when combined with artemisinin-combination therapy.
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Background
Malaria elimination is presently considered as a demand-
ing, but achievable objective, even though in 2018 alone 
there were over 200 million new cases of malaria and 
405,000 deaths. Of the deaths, 93% occurred in sub-Saha-
ran Africa [1]. This figure reflects the important malaria 
burden but also the positive developments witnessed in 
recent years in the reduction of worldwide burden of the 
disease [2]. Together with vector control interventions, 
the use of artemisinin-based combination therapy (ACT) 
has contributed considerably to the decline in the malaria 
incidence and prevalence in many sub-Saharan countries 
[3, 4].
Elimination efforts may benefit from transmission-
blocking interventions, including the use of gameto-
cytocidal drugs to prevent Plasmodium falciparum 
transmission and support containment efforts for arte-
misinin-resistant parasites. The 8-aminoquinoline pri-
maquine, presently represents the only widely available 
drug option to clear mature P. falciparum gametocytes 
[5, 6]. Until 2012, the World Health Organization (WHO) 
recommended a single dose of primaquine at 0.75 mg/kg 
in combination with ACT to treat uncomplicated P. fal-
ciparum in G6PD normal patients [7]. This has recently 
been amended to a single low-dose (0.25 mg/kg) of pri-
maquine regardless of the G6PD status, reducing the risk 
of acute haemolytic reactions in this vulnerable popula-
tion [8]. However, current policies of some countries 
such as India and Guyana are still using 0.75 mg/kg dose 
of primaquine with ACT to treat uncomplicated P. falci-
parum malaria even in G6PD deficient patients [9, 10].
The timing of primaquine when co-administered with 
ACT may have consequences for primaquine efficacy, 
safety and compliance [11]. Since ACT effectively clears 
immature gametocytes, but not mature gametocytes 
[12], it is conceivable that relatively late dosing of pri-
maquine may be optimal to clear persisting gametocytes. 
Late primaquine dosing has also been suggested as an 
approach to reduce haemolytic effects of treatment that 
are observed after ACT and may be aggravated by pri-
maquine [13, 14]. Additionally, primaquine on the first 
day of treatment may worsen nausea and vomiting, com-
mon malaria presenting symptoms, due to its associated 
gastrointestinal effects. Patients may better tolerate these 
symptoms if primaquine is administered on day 3 or 
later of the treatment [11]. However, administering pri-
maquine on the first day of ACT has operational advan-
tages to ensure compliance because patients can receive 
the treatment at the clinic once diagnosed with malaria 
as a directly observed therapy.
The optimal timing of primaquine in combination with 
ACT in terms of safety and efficacy is relevant for policy-
makers to decide on the best strategy before wide-scale 
implementation of ACT-primaquine. The current study 
thus aimed to determine the optimal timing of a single 
dose of primaquine administered on either day 1 or 3 in 
combination with ACT for clearing microscopic and sub-
microscopic gametocytaemia.
Methods
Study area
This study was conducted at Bagamoyo district hospital 
and Kiwangwa dispensary, Tanzania between May 2013 
and July 2015. The trial centre was at Bagamoyo Research 
and Training Centre (BRTC) of Ifakara Health Institute 
(IHI) where all laboratory investigations were conducted. 
Malaria prevalence in the study area is estimated to be 
41% by RDT [15]. Plasmodium falciparum is the pre-
dominant malaria species and the main vector is Anoph-
eles gambiae sensu stricto [16].
Study design
This was a randomized open label clinical trial determin-
ing the safety and efficacy of primaquine co-administered 
at a different time with artemether–lumefantrine (AL) 
treatment regimen. Recruitment of patients involved 
screening at two stages. The first screening took place in 
Bagamoyo district hospital, Kiwangwa dispensary and 4 
satellite clinics. This screening selected patients with the 
following characteristics; aged between 3 and 17  years, 
parasitaemia of 1000–50,000 parasite/µl, haemoglo-
bin level ≥ 9  g/dl by HemoCue (Angelholm, Sweden), 
axillary temperature > 37.5  °C and < 39.5  °C or history 
of fever in the last 48 h, no history of adverse reactions 
to study medication, no evidence of chronic disease or 
acute infection other than malaria, not treated with anti-
malarial chemotherapy in the past 2  weeks, the ability 
to swallow oral medication, willing to provide written 
informed consent and comply to study protocol. Partici-
pants meeting criteria in satellite clinics were referred to 
the two study facilities for additional screening and were 
enrolled after microscopic confirmation for P. falciparum 
mono-infection and when confirmed to be G6PD normal 
by rapid enzyme chromatographic test (CareStartTM, 
Access Bio, Inc. New Jersey, USA).
ClinicalTrials.gov Registration NCT01906788
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The study was designed to have three treatment groups 
(1, 2 and 3). Upon meeting all enrolment criteria, par-
ticipants were randomized to receive either of the three 
treatment regimens; (i) AL (Coartem; Novartis Pharma 
AG, Basel Switzerland—20  mg artemether and 120  mg 
lumefantrine) as a standard six-dose regimen for uncom-
plicated malaria in Tanzania, (ii) AL and a single 0.75 mg/
kg primaquine dose on the first day of AL (day 1 or early 
primaquine), and (iii) AL and single 0.75  mg/kg pri-
maquine dose on the last day of AL (day 3 or late pri-
maquine). A tablet of 15 mg primaquine (Sanofi Aventis, 
Mumbai, India) was used. For young children, a tablet(s) 
adjusted to 0.75 mg/kg dose was crushed and dissolved in 
15 mL of clean water and administered orally. All partici-
pants were encouraged to eat food before treatment. First 
dose of AL and primaquine (on day 1 and 3) were given 
under supervision. Treatment was closely monitored and 
those vomited within the first 30  min after drug intake 
were given a second full dose.
Randomization
Computer generated list of random numbers was used 
to assign participants into either of the three treatment 
groups. The sequential list of numbers was matched 
with treatment group assignments 1, 2 or 3 was pre-
pared and handed to study clinician and was secured 
in a locked cabinet. Only the study clinician and nurse 
were aware of treatment assignment. Participants and all 
other study personnel including field workers and people 
working in the laboratory were blinded to the treatment 
assignments.
Procedures
The treatment was initiated on day 1 (day of enrolment). 
Participants were asked to return to the study clinic on 
days 2, 3, 4 8, 11 and 15. On each follow-up day, study 
participants were assessed for any symptoms, possible 
adverse events, concomitant medication, measuring axil-
lary temperature and collecting blood samples. In case a 
participant did not show up at the clinic, a field worker 
was sent to the house to find out the reason and possibly 
to bring the participant at the clinic for clinical examina-
tion and sampling. At all visits, finger-prick blood sam-
ples were collected for blood smears, RNA collection 
in guanidine isothiocyanate-containing L6 lysis buffer 
(50 μL of blood in 950 μL buffer) for Pfs25 mRNA quan-
titative nuclear acid sequence based quantification (QT-
NASBA), and haemoglobin level measurements.
Blood slides were stained for 10 min with 10% Giemsa 
and screened for asexual parasite and gametocytes. Slides 
were declared negative if no parasites are observed in 
100 microscopic fields; asexual parasites and gameto-
cytes counted against 200 and 500 white blood cells, 
respectively. All slides were examined independently by 
two experienced technicians using a light microscope. 
Discrepant findings were reviewed by a third technician 
until consensus on positivity was reached.
The blood sample collected for QT-NASBA analysis 
was used to extract RNA first in the field following the 
original Guanidine isothiocyanate (GuSCN) RNA extrac-
tion method [17] and transferred to a laboratory in the 
Netherlands for completion of the extraction. Nucleic 
acids were extracted by the Boom upon which Pfs25 
mRNA QT-NASBA was performed on a NucliSens 
EasyQ analyser (bioMérieux, Boxtel, The Netherlands). 
Gametocyte density was assessed using a trendline of 
mature stage V gametocytes, as previously reported by 
Shekalaghe et al. [14].
All clinical and laboratory data were carefully recorded 
in case record form. Data was double entered into elec-
tronic database by experienced data entry clerks. The 
accuracy of data input was checked and validated using a 
customized validation program. Data was then converted 
to Stata dataset for analysis.
Study end‑points
The primary end-point was gametocyte prevalence and 
density by microscopy and QT-NASBA on day 8, 11 and 
15. The secondary end-point was the mean reduction of 
haemoglobin concentration (g/dl) between baseline and 
day 4, 8, 11 and 15.
Sample size
The sample size was decided upon based on an assumed 
duration of gametocyte carriage by Pfs25 QT-NASBA of 
5.2 days (sd = 3.5) with AL-d3 primaquine [14, 18]. It was 
considered that an increase or reduction in the duration 
of gametocyte carriage of less than 1.5 days was of lim-
ited relevance. With one-sided testing against a p value 
of 0.05 with 80% power, the authors determined that 
including 100 individuals at the ratio of 1:1:1 in the three 
treatment arms would detect differences in the duration 
of gametocytes carriage of ≥ 1.5 allowing for 10% lost to 
follow-up. This sample size was not achieved, due to very 
low inclusion numbers as a result of much lower clinical 
incidence than anticipated based on historical data.
Statistical analysis
STATA ® 14.0 (Stata Corporation, College Station, 
Texas, USA) was used for data analysis. Numerical var-
iables were summarized as mean and standard devia-
tion. Categorical variables were summarized using 
cross tabulation to estimate differences in proportions. 
The mean time to gametocyte clearance was estimated 
for each treatment arm using a non-linear model. A 
95% confidence interval (CI) was used to determine 
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the difference in gametocyte prevalence between 
intervention arms (early and late primaquine treat-
ment) and the control arm. Gametocyte prevalence on 
different visit days was compared between study arms 
by Chi square or Fisher’s exact test with a two-sided 
Chi square P-value presented. The area under the 
curve (AUC) of Pfs25 QT-NASBA gametocyte den-
sity versus time was used to determine the effect of 
treatment. This measure incorporates the duration of 
gametocyte carriage, from days 0 to 15. A paired t-test 
was used to compare the changes in haemoglobin level 
across different time points.
Ethical consideration
This study was conducted in accordance with the Dec-
laration of Helsinki, ICH Good Clinical Practice, and 
local regulatory requirements from the Tanzania Food 
and Drug Authority (TFDA). The study is registered 
with ClinicalTrials.gov (number NCT01906788). Ethi-
cal approval was granted by IHI ethical review board 
and the National Institute for Medical Research ethi-
cal committee (number NIMR/HQ/R.8c/Vol.II/370). 
Assent and written informed consent was obtained 
from participants and their parents/guardians, 
respectively.
Results
A total of 556 participants were screened for eligibility, 
432 (77.7%) and 13 (2.3%) were excluded during primary 
and secondary screening, respectively. Hundred and 
eleven (20.0%) were enrolled; 36, 38 and 37 were ran-
domly assigned to AL only, AL + day 1 primaquine and 
AL + day 3 primaquine arm, respectively. Three partici-
pants in AL only arm and 1 in AL + day 3 primaquine 
were lost during follow up period (Fig.  1). The overall 
median and interquartile range [IQR] age at enrolment 
was 7 (5–11) years. Median (IQR) asexual parasite den-
sity at baseline was 218 (101–643) parasites/µL, gameto-
cyte density was 3.3 (2.6–3.9) log adjusted gametocytes 
density/mL and haemoglobin level was 10.6 (9.5–11.6) g/
dl (Table 1).
Gametocyte assessment by QT-NASBA, gameto-
cytes were detected up to day 11 for AL only arm (3.3% 
[1/30]). For AL + day 1 primaquine and AL + day 3 pri-
maquine gametocyte was detected up to day 4 (11.1% 
[4/35]) and day 8 (6.4% [2/31]), respectively. No game-
tocytes were detected on day 15 of follow-up in any of 
the treatment arms. From the baseline, the prevalence 
of participants with gametocytes steadily decreased 
in all of the three arms. Day 4 gametocyte prevalence 
in AL + day 1 primaquine was half the level seen in 
either AL + day 3 primaquine or AL only arm (4/35 vs 
8/31 and 8/30, respectively) although not statistically 
556 assessed for eligibility
13 excluded in secondary 
screening
5 had mixed infecon
4 were G6PD deficient
4 refused to parcipate  
432 excluded in primary screening
AL only
(n = 36)
AL+Primaquine Day 1
(n = 38)
AL+Primaquine Day 3
(n = 37)
33 completed follow-up
- 30 (90%) in QT-NASBA 
gametocyte analysis
3 lost to 
follow up
37 completed follow-up
- 31 (84%) in QT-NASBA 
gametocyte analysis
37 completed follow-up
- 35 (95%) in QT-NASBA 
gametocyte analysis
1 lost to 
follow up
Fig. 1 Trial profile
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significant. Day 8 gametocyte prevalence in AL only 
arm was the highest (13.3% [4/30]) compared to 
AL + day 1 primaquine (0.0% [0/35]) and + day 3 pri-
maquine (6.4% [2/31]) arm (Tables 2 and 3).
Mean gametocyte density decreased in all three treat-
ment arms from day 1 to day 4 with a mean difference 
of 0.754 mL, 0.063 mL, and 1.147 mL in AL only arm, 
AL + day 1 primaquine and AL + day 3 primaquine, 
respectively, but the difference across the three arms 
was not statistically significant., except for AL + day 3 
primaquine arm. In the few remaining gametocyte car-
riers, day 8 mean (sd) gametocyte density in AL + day 
3 primaquine arm increased from 2.252 (1.296) mL on 
day 4 to 3.135 (1.396) mL. Two participants in AL + day 
3 primaquine had day 8 mean gametocyte density of 
3.135 mL that decreased by 0.539 mL when compared 
with the density of day 4 (Fig.  2). AUC of gametocyte 
density versus time was not statistically significant 
(p = 0.5319) (Table 2).
Baseline haemoglobin value was used as a reference to 
determine relative changes in participant’s haemoglobin 
level during the follow-up period. The mean (SD) drop of 
Table 1 Baseline characteristics
AL artemether–lumefantrine, SD standard deviation
Characteristics Treatment arm p‑value
AL only (n = 33) AL + primaquine day 1 (n = 37) AL + primaquine day 3 (n = 37)
Male sex (%) 17 (51.5) 20 (54.1) 15 (40.5) 0.469
Mean age (SD; range) 8.5 (4.0; 3–17) 7.9 (3.2; 3–16) 7.5 (3.9; 3–17) 0.365
Mean haemoglobin (SD; range) 11.1 (1.2; 9–14) 10.9 (1.6; 9.1–13.8) 10.2 (1.2; 8.7–13.9) 0.441
Mean parasitaemia density (SD; range) 413.3 (596.0; 29–3205) 433.7 (354.7; 28–1116) 349 (317.4; 28–1030) 0.424
Table 2 Asexual and gametocyte prevalence during follow up
AL artemether–lumefantrine, AUC area under the curve; CI confidence interval
*P-value across the three treatment arms
AL only AL + primaquine day 1 AL + primaquine day 3 P‑value P‑value
% (n/N) % (n/N) % (n/N) (AL only vs 
AL + primaquine 
day 1)
(AL only vs 
AL + primaquine 
day 3)
Asexual parasite prevalence by microscopy
 Day 2 15.1 (5/33) 24.3 (9/37) 13.5 (5/37) 0.338 0.845
 Day 3 0 0 0 – –
AL only AL + primaquine day 1 AL + primaquine day 3
Gametocyte prevalence by QT-NASBA
 Day 1 90 (27/30) 82.8 (29/35) 96.8 (30/31) 0.474 0.437
 Day 4 26.7 (8/30) 11.4 (4/35) 25.8 (8/31) 0.364 0.382
 Day 8 13.3 (4/30) 0.0 (0/35) 6.4 (2/31) – 0.306
 Day 11 3.3 (1/30) 0.0 (0/35) 0.0 (0/31) – –
 Mean AUC (95% CI) of 
gametocyte density 
versus time*
0.523 (0.467 – 0.579) 0.530 (0.475 – 0.584) 0.508 (0.450 – 0.563) 0.5319
Table 3 Day 4 and day 8 gametocyte prevalence adjusted 
for baseline gametocyte density
AL artemether–lumefantrine, OR odds ratio, CI confidence interval
Variable Gametocyte 
prevalence 
n/N
OR (95% CI) p value
Day 4 prevalence
 AL only 8/30 Ref.
 AL + primaquine day 1 4/35 0.28 (0.06 – 1.37) 0.116
 AL + primaquine day 3 8/31 0.79 (0.21 – 3.00) 0.726
Day 8 prevalence
 AL only 4/30 Ref.
 AL + primaquine day 1 0/35 – –
 AL + primaquine day 3 2/31 0.51 (0.07 – 3.60) 0.502
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haemoglobin on day 2 was − 0.91 (1.3) g/dl, − 0.92 (1.0) 
g/dl and − 0.42 (1.2) g/dl in the AL only, AL + day 1 pri-
maquine and AL + day 3 primaquine arms, respectively. 
Haemoglobin gradually decreased from the baseline val-
ues on day 3 and 4 in all of the treatment arms. Day 8 
mean drop of haemoglobin was − 0.86 (1.3) g/dl, − 1.26 
(1.7) g/dl and − 0.18 (1.2) g/dl for AL only, AL + day 1 
primaquine and AL + day 3 primaquine arm, respectively. 
Haemoglobin level in AL + day 3 primaquine recovered 
by 0.35 (1.5) g/dl on day 15 of follow up but was not the 
case in AL only [− 0.39 (1.3)] g/dl and AL + day 1 pri-
maquine [− 0.65 (1.3)] g/dl arms in the same follow up 
day. The general pattern shows initial sharp decline of 
haemoglobin level followed by a slow recovery, however, 
the difference between arms was not statistically signifi-
cant (p = 318) (Fig. 3).
Twenty-six (23.4%) participants reported a total of 31 
mild adverse events; 9 (34.6%) AL only, 6 (23.1) AL + day 
1 primaquine and 11 (42.3) AL + day 3 primaquine arm 
(Table  4). All adverse events were reported in the first 
8  days of follow up, 44% of these adverse events were 
reported on day 2. None of the participants was admit-
ted during the follow-up period as a result of adverse 
event or for any reason. Cough (34.6%) was the most 
commonly reported adverse event followed by headache 
(26.9%). There was no significant difference in terms of 
proportion or specific adverse events reported between 
the three treatment arms.
Across arms, 23% (26/111) of participants reported 
a total of 31 mild adverse events; no statistically signifi-
cant difference in the occurrence of adverse events was 
observed between arms (p = 0.477).
Discussion
The study observed that single full-dose primaquine 
administered with AL on day 1 cleared gametocytes 
faster than day 3 administration although not statistically 
significant. Primaquine was well tolerated in both inter-
vention arms with no serious adverse events. No clini-
cally relevant haemolysis was observed; adverse events 
and reductions in haemoglobin concentration were not 
significantly different between the control and the two 
primaquine arms.
Primaquine taken on the first day of AL resulted in the 
complete absence of gametocytes after the fourth day of 
treatment initiation as opposed to participants given on 
the last day of AL in which gametocytes were absent after 
the eighth day. This suggests that ACT-early primaquine 
effectively clears both immature and mature gameto-
cytes and makes onward transmission to mosquitoes very 
unlikely within days after initiation of treatment [11].
Gametocytes in the control arm were detectable until 
day 11. This contrasts with a similar study conducted 
in Mali that observed about 90% of patients with game-
tocytes on day 28 of follow up following AL treatment 
[19]. The latter study from Mali enrolled high-density 
0
2
4
6
AL only                               AL+Primaquine Day  1                          AL+Primaquine Day 3
Day 1 Day 4 Day 8
Fig. 2 Mean gametocyte concentration measured by QT-NASBA (n = 96)
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gametocyte carriers only; this is the most likely expla-
nation for the observed difference. In addition, AL is 
superior to dihydroartemisinin–piperiaquine, the ACT 
used in Mali, in terms of gametocyte reduction. The 
importance of primaquine for preventing transmission 
shortly after ACT treatment has been demonstrated 
for dihydroartemisinin–piperaquine [19, 20] and, with 
some conflicting findings, for AL [20, 21].
In the current study, mean haemoglobin declined in 
all of three treatment arms and started to recover from 
day 7 of treatment. This may be explained by acute hae-
molysis of parasitized blood cells after treatment with 
-6
-4
-2
0
2
4
Day 2 Day 3 Day 4 Day 8 Day 11 Day 15
AL only AL+Primaquine Day 1 AL+Primaquine Day 3
Fig. 3 Mean absolute change in haemoglobin concentration per treatment arm (n = 107)
Table 4 Self-reported complaints post day 1 of treatment ‘adverse events’
AL artemether–lumefantrine
*44% of adverse events were reported on day 2 of follow up
Adverse effects AL only AL + primaquine day 1 AL + primaquine 
day 3
Participants with adverse events (%) 9 (34.6) 6 (23.1) 11 (42.3)
Number of adverse events* 10 8 13
Cough 4 3 2
Skin rush 1 0 0
Headache 2 1 4
Dizziness 1 0 0
Abdominal discomfort/pain 2 2 1
Loss of appetite 0 1 2
Vomiting 0 0 1
Diarrhoea 0 0 1
Otitis media 0 1 0
Conjunctivitis 0 0 1
Painful micturition 0 0 1
Page 8 of 9Shekalaghe et al. Malar J           (2020) 19:34 
ACT [22]. Previous studies in uncomplicated P. falci-
parum patients have demonstrated similar haemoglo-
bin drops following ACT treatment with or without 
0.75  mg/kg or 0.25  mg/kg single dose of primaquine 
[23–25]. Slow haemoglobin recovery in primaquine 
day 1 arm may be explained by the effect of primaquine 
administration on the first day of treatment that may 
worsen the natural drop in haemoglobin which is typi-
cally seen shortly after clearance of malaria parasite 
[11]. However, there is no significant difference in 
haemoglobin trend through the follow up period but 
sample size may have been too small to detect subtle 
differences.
There were no serious adverse events reported in the 
study and milder adverse events were often unrelated to 
treatment and not different between arms.
These results, however, were not statistically significant 
due to sample size, so the need for further studies should 
be emphasized, which could use the 0.25  mg/kg WHO 
recommended primaquine dose instead of 0.75  mg/kg 
[8], and include adults as well as G6PD deficient patients 
for whom this dose is considered safer in terms of 
haemolytic risk. In such study, haemoglobin drops could 
be followed carefully to address the slower recovery seen 
in this study for the day 1 primaquine arm (this difference 
was also not statistically significant in this study).
Conclusion
The study provided significant information to optimal 
timing of primaquine in the new WHO recommendation 
that requires co-administration of ACT with a single low-
dose of primaquine (0.25 mg/kg) to patients with P. fal-
ciparum malaria [8]. Among other reasons, primaquine 
use on the first day of ACT is equally safe, tolerable and 
appears superior to late primaquine treatment in terms 
of gametocyte reduction.
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